Last checked at 28 Feb 2022 17:00
28 February 2022
Cizzle Biotechnology Holdings Plc
("Cizzle Biotechnology" or the "Company")
Total Voting Rights
Cizzle Biotechnology, the UK based diagnostics developer, makes the following announcement in accordance with Rule 5.6.1 of the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
As of 28 February 2022, the Company's issued ordinary share capital consists of 278,447,788 ordinary shares of 0.01 pence each, each with one voting right. The Company holds no ordinary shares in Treasury. Therefore, the Company's total number of ordinary shares and voting rights is 278,447,788 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
Enquiries:
Cizzle Biotechnology Holdings plc | Via IFC Advisory |
Allan Syms (Executive Chairman) |
|
Allenby Capital Limited | +44(0) 20 33285656 |
John Depasquale |
|
Alex Brearley |
|
Novum Securities Limited | +44(0) 20 7399 9400 |
Colin Rowbury Jon Bellis |
|
IFC Advisory Limited | +44(0) 20 3934 6630 |
Tim Metcalfe | cizzle@investor-focus.co.uk |
Florence Chandler |
|
Notes to Editors:
About Cizzle Biotechnology
Cizzle Biotechnology is developing a blood test for the early detection of lung cancer. Cizzle Biotechnology is a spin- out from the University of York, founded in 2006 around the work of Professor Coverley and colleagues. Its proof-of-concept prototype test is based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted CIZ1B variant is highly correlated with early-stage lung cancer.
For more information, please see https://cizzlebiotechnology.com
You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.